Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Marino, Nalini ^a   Illingworth, Sam ^a   Kodialbail, Prithvi ^a   Patel, Ashvin ^a   Calderon, Hugo ^a   Lear, Rochelle ^a   Fisher, Kerry D ^a   Champion, Brian R ^a   Brown, Alice C N ^a  

^a PSIOXUS THERAPEUTICS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENADENOTUCIREV; NG 285 ONCOLYTIC VIRUS; NG 61 ONCOLYTIC VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG POTENCY; GENE CASSETTE; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFE CYCLE; LUNG CARCINOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; SINGLE DRUG DOSE; TRANSGENE; TUMOR CELL; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS PARTICLE; ADENOVIRIDAE; GENETICS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; PROCEDURES; REPORTER GENE; VIROLOGY;

ADENOVIRIDAE; GENE EXPRESSION; GENES, REPORTER; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSGENES;

EID: 85019381089     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0177810     Document Type: Article

References (42)

1. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. https://doi.org/10.1200/JCO.2014.58.3377 PMID: 26014293
2. Greig SL. Talimogene Laherparepvec: First Global Approval. Drugs. 2016; 76(1):147-54. https://doi.org/10.1007/s40265-015-0522-7 PMID: 26620366
3. Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2016.
4. Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2016; 5(2):e1117740. PubMed Central PMCID: PMCPMC4801444. https://doi.org/10.1080/2162402X.2015.1117740 PMID: 27057469
5. Keller BA, Bell JC. Oncolytic viruses-immunotherapeutics on the rise. J Mol Med (Berl). 2016.
6. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007; 15(4):651-9. https://doi.org/10.1038/sj.mt.6300108 PMID: 17299401
7. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014; 14(8):559-67. https://doi.org/10.1038/nrc3770 PMID: 24990523
8. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014; 6(226):226ra32. PubMed Central PMCID: PMCPMC4106918. https://doi.org/10.1126/scitranslmed.3008095 PMID: 24598590
9. Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther. 2014; 22(1):123-31. PubMed Central PMCID: PMCPMC3978812. https://doi.org/10.1038/mt.2013.238 PMID: 24343053
10. Wang S, Li X, Wang P, Li H, Du X, Liu M, et al. The efficacy of oncolytic adenovirus is mediated by T cell responses against virus and tumor in Syrian hamster model. Clin Cancer Res. 2016.
11. Tahtinen S, Gronberg-Vaha-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, et al. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. Cancer Immunol Res. 2015; 3(8):915-25. https://doi.org/10.1158/2326-6066.CIR-14-0220-T PMID: 25977260
12. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010; 17(3):718-30. https://doi.org/10.1245/s10434-009-0809-6 PMID: 19915919
13. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013; 19(3):329-36. PubMed Central PMCID: PMCPMC4268543. https://doi.org/10.1038/nm.3089 PMID: 23396206
14. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. https://doi.org/10.1016/j.immuni.2013.07.012 PMID: 23890059
15. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016; 15(4):235-47. https://doi.org/10.1038/nrd.2015.35 PMID: 26965203
16. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013; 342(6165):1432-3. https://doi.org/10.1126/science.342.6165.1432 PMID: 24357284
17. Burns MC, O'Donnell A, Puzanov I. Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs. 2016; 4(8):867-73. PubMed Central PMCID: PMCPMC5010088. https://doi.org/10.1080/21678707.2016.1191348 PMID: 27597930
18. Buchbinder EI, Hodi FS. Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol. 2016; 13(2):77-8. https://doi.org/10.1038/nrclinonc.2015.237 PMID: 26787285
19. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. https://doi.org/10.1016/S0140-6736(16)00587-0 PMID: 26970723
20. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. https://doi.org/10.1056/NEJMoa1504030 PMID: 26027431
21. Marquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, Gonzalez-Cao M, et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med. 2015; 3(18):267. PubMed Central PMCID: PMCPMC4630549. https://doi.org/10.3978/j.issn.2305-5839.2015.10.27 PMID: 26605313
22. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. https://doi.org/10.1056/NEJMoa1414428 PMID: 25891304
23. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26):2521-32. https://doi.org/10.1056/NEJMoa1503093 PMID: 25891173
24. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016.
25. Marrone KA, Ying W, Naidoo J. Immune-Related Adverse Events From Immune Checkpoint Inhibitors. Clin Pharmacol Ther. 2016; 100(3):242-51. https://doi.org/10.1002/cpt.394 PMID: 27170616
26. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54:139-48. https://doi.org/10.1016/j.ejca.2015.11.016 PMID: 26765102
27. Tartari F, Santoni M, Burattini L, Mazzanti P, Onofri A, Berardi R. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. Cancer Treat Rev. 2016; 48:20-4. https://doi.org/10.1016/j.ctrv.2016.06.002 PMID: 27310708
28. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009; 113(9):1909-18. PubMed Central PMCID: PMCPMC2651010. https://doi.org/10.1182/blood-2008-09-178459 PMID: 19131551
29. Fisher K. Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther. 2006; 8(4):301-13. PMID: 16955693
30. Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008; 3(6):e2409. PubMed Central PMCID: PMCPMC2423470. https://doi.org/10.1371/journal.pone.0002409 PMID: 18560559
31. Di Y, Seymour L, Fisher K. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther. 2014; 21(4):440-3. https://doi.org/10.1038/gt.2014.2 PMID: 24553347
32. Calvo E, Gil-Martin M, Cubillo A, Machiels J- P, Rottey S, Mardjuadi FI, et al. A Phase I study of enadenotucirev, an onclytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously - analysis of dose expansion and repeat cycle cohorts n patients with metastatic colorectal cancer (mCRC). Annals of Oncology. 2014; 25(Suppl 4):iv367.
33. Cawood R, Hills T, Wong SL, Alamoudi AA, Beadle S, Fisher KD, et al. Recombinant viral vaccines for cancer. Trends Mol Med. 2012; 18(9):564-74. https://doi.org/10.1016/j.molmed.2012.07.007 PMID: 22917663
34. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol. 1993; 67(10):5911-21. PubMed Central PMCID: PMCPMC238011. PMID: 8371349
35. Jin F, Kretschmer PJ, Hermiston TW. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol Ther. 2005; 12(6):1052-63. https://doi.org/10.1016/j.ymthe.2005.07.696 PMID: 16165398
36. Knipe DM, Howley PM. Fields Virology. 6th ed: Lippincott Williams and Wilkins; 2013.
37. Bird SW, Kirkegaard K. Escape of non-enveloped virus from intact cells. Virology. 2015;479-480:444-9. PubMed Central PMCID: PMCPMC4440412.
38. Calvo E, Gil-Martin M, Machiels J-P, Rottey S, Cubillo A, Salazar R, et al. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumours. J Clin Oncol. 2014; 32:5s:(suppl; abstr 3103).
39. McNeish I, Agnieszka M, Twelves C, Glasspool R, Ajaz M, Morrison R, et al. A phase I/II studcy of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epthelial ovarian cancer. Journal of Clinical Oncology. 2015; 33(15-suppl):TPS5611.
40. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006; 12(22):6737-47. https://doi.org/10.1158/1078-0432.CCR-06-0759 PMID: 17121894
41. Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol Med. 2007; 130:223-35. PMID: 17401177
42. Alcoser SY, Kimmel DJ, Borgel SD, Carter JP, Dougherty KM, Hollingshead MG. Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts. BMC Biotechnol. 2011; 11:124. PubMed Central PMCID: PMCPMC3281124. https://doi.org/10.1186/1472-6750-11-124 PMID: 22176647